Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
Gene therapy of cancer is a novel approach with the potential to selectively eradicate tumour cells, whilst sparing normal tissue from damage. In particular, gene-directed enzyme prodrug therapy (GDEPT) is based on the delivery of a gene that encodes an enzyme which is non-toxic per se, but is able to convert a prodrug into a potent cytotoxin. Several GDEPT systems have been investigated so far, demonstrating effectiveness in both tissue culture and animal models. Based on these encouraging results, phase I/II clinical trials have been performed and are still ongoing. The aim of this review is to summarise the progress made in the design and application of GDEPT strategies. The most widely used enzyme/prodrug combinations already in clinical trials (e.g., herpes simplex 1 virus thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine), as well as novel approaches (carboxypeptidase G2/CMDA, horseradish peroxidase/indole-3-acetic acid) are described, with a particular attention to translational research and early clinical results.
Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount-Verion Hospital, Northwood, Middlesex, UK.
O
O
Greco
G U
GU
Dachs
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D057487:Enzyme Therapy; D004798:Enzymes / Q000235:genetics / Q000378:metabolism; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use*; D014176:Protein Biosynthesis
D000970:Antineoplastic Agents; D004798:Enzymes; D011355:Prodrugs